Nvidia (NVDA) rose about +1% in pre-market trading after the chipmaker posted better-than-expected Q4 results and issued largely in-line Q1 revenue guidance ... (BECN), Starwood Property (STWD), ADT ...

Economists expect the U.S. economy to expand at an annual rate of 2.3% in the fourth quarter, in line with initial estimates ...

Nvidia (NVDA) was little changed in pre-market trading after the chipmaker posted better-than-expected Q4 results and issued largely in-line Q1 revenue guidance ... Starwood Property (STWD), ADT (ADT) ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close. Amicus Therapeutics (FOLD) reported earnings 30 days ago.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Are such expectations realistic? We think the likelihood of belied expectations looms as the central bank appears to be working with an outmoded compass amid a tempest. The Lucas critique that ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The Marc Healing Center is Phase II of Compass Health's three-phase Broadway Campus Redevelopment. EVERETT, Wash., Feb. 24, 2025 (GLOBE NEWSWIRE) -- On Broadway Avenue in Everett’s core ...